Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets
Authors:
- Jin-Jing PeiJPJin-Jing Pei
- Magnus SjögrenMagnus Sjögren
- Bengt WinbladBWBengt Winblad
- 1 November 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 21 (6) , 555-561
Abstract
Great progress has been made in understanding the pathogenesis of neurofibrillary degeneration in Alzheimer's disease brains in the last two decades. In this review we summarize how neurons are degenerated in Alzheimer's disease brains and highlight the evidence of using kinases such as glycogen synthase kinase 3 and p70 S6 kinase and phosphatases such as protein phosphatase 2A as drug targets to prohibit the formation of neurofibrillary degeneration of Alzheimer's disease. In general there are two types of neuronal degeneration in Alzheimer's disease brains: neurofibrillary formation and apoptosis. The microtubule-associated protein tau that stabilizes neuronal microtubules under normal physiological conditions is abnormally hyperphosphorylated in Alzheimer's disease brains, resulting in the generation of aberrant aggregates that are toxic to neurons. The processes of tau hyperphosphorylation and the formation of neurofibrillary tangles are caused by the imbalance of the activities of protein kinases and protein phosphatases in Alzheimer's disease brains. Recent findings from our and other groups have suggested glycogen synthase kinase 3 and p70 S6 kinase as main tau kinases and protein phosphatase 2A as the main tau phosphatase involved in the formation of these processes. Activities of these targets are implicated by Aβ peptide, the major component of another hallmark in Alzheimer's disease brains, senile plaques. To prevent the clinical progression of neurodegeneration, a combination strategy is suggested to target both senile plaques with immunization and neurofibrillary tangles with drugs to prevent the synthesis and phosphorylation of tau.Keywords
This publication has 68 references indexed in Scilit:
- Tau pathology in Alzheimer disease and other tauopathiesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Amyloid β Pathology in Alzheimer’s Disease and SchizophreniaAmerican Journal of Psychiatry, 2003
- Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain BankAlzheimer Disease & Associated Disorders, 2002
- Characterization of neuronal dystrophy induced by fibrillar amyloid β: implications for Alzheimer’s diseaseNeuroscience, 2002
- Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive DeclineJAMA, 2000
- Amyloid β-Protein and the Genetics of Alzheimer's DiseaseJournal of Biological Chemistry, 1996
- Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s DiseaseThe Journal of Neuroscience, 1996
- Neurochemical Correlates of Dementia Severity in Alzheimer's Disease: Relative Importance of the Cholinergic DeficitsJournal of Neurochemistry, 1995
- Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's diseaseNeurology, 1992
- ALZHEIMER’S DISEASE —AN ELECTRON MICROSCOPICAL STUDYBrain, 1964